Literature DB >> 25685309

EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.

Jennifer L Woodring1, Gautam Patel1, Jessey Erath2, Ranjan Behera3, Patricia J Lee4, Susan E Leed4, Ana Rodriguez5, Richard J Sciotti4, Kojo Mensa-Wilmot3, Michael P Pollastri1.   

Abstract

Target repurposing is a proven method for finding new lead compounds that target Trypanosoma brucei, the causative agent of human African trypanosomiasis. Due to the recent discovery of a lapatinib-derived analog 2 with excellent potency against T. brucei (EC50 = 42 nM) and selectivity over human host cells, we have explored other classes of human tyrosine kinase inhibitor scaffolds in order to expand the range of chemotypes for pursuit. Following library expansion, we found compound 11e to have an EC50 of 84 nM against T. brucei cells while maintaining selectivity over human hepatocytes. In addition, the library was tested against causative agents of Chagas' disease, leishmaniasis, and malaria. Two analogs with sub-micromolar potencies for T. cruzi (4j) and Plasmodium falciparum (11j) were discovered, along with an analog with considerable potency against Leishmania major amastigotes (4e). Besides identifying new and potent protozoan growth inhibitors, these data highlight the value of concurrent screening of a chemical library against different protozoan parasites.

Entities:  

Year:  2015        PMID: 25685309      PMCID: PMC4324364          DOI: 10.1039/C4MD00441H

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  22 in total

1.  Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Authors:  Nicholas D Bland; Cuihua Wang; Craig Tallman; Alden E Gustafson; Zhouxi Wang; Trent D Ashton; Stefan O Ochiana; Gregory McAllister; Kristina Cotter; Anna P Fang; Lara Gechijian; Norman Garceau; Rajiv Gangurde; Ron Ortenberg; Mary Jo Ondrechen; Robert K Campbell; Michael P Pollastri
Journal:  J Med Chem       Date:  2011-11-08       Impact factor: 7.446

2.  Lapatinib.

Authors:  Beverly Moy; Peter Kirkpatrick; Santwana Kar; Paul Goss
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

3.  Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.

Authors:  Robert D Hubbard; Scott H Dickerson; Holly K Emerson; Robert J Griffin; Michael J Reno; Keith R Hornberger; David W Rusnak; Edgar R Wood; David E Uehling; Alex G Waterson
Journal:  Bioorg Med Chem Lett       Date:  2008-09-27       Impact factor: 2.823

Review 4.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

5.  1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.

Authors:  Yijun Huang; Siglinde Wolf; Michal Bista; Lidio Meireles; Carlos Camacho; Tad A Holak; Alexander Dömling
Journal:  Chem Biol Drug Des       Date:  2010-05-18       Impact factor: 2.817

Review 6.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Authors:  José Baselga; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

Review 7.  Small molecule inhibitors of the class 1 receptor tyrosine kinase family.

Authors:  G Stuart Cockerill; Karen E Lackey
Journal:  Curr Top Med Chem       Date:  2002-09       Impact factor: 3.295

8.  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Authors:  Stefan O Ochiana; Vidya Pandarinath; Zhouxi Wang; Rishika Kapoor; Mary Jo Ondrechen; Larry Ruben; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2012-07-31       Impact factor: 6.514

9.  Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.

Authors:  Gautam Patel; Norma E Roncal; Patricia J Lee; Susan E Leed; Jessey Erath; Ana Rodriguez; Richard J Sciotti; Michael P Pollastri
Journal:  Medchemcomm       Date:  2014-05-01       Impact factor: 3.597

10.  The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.

Authors:  Rosario Diaz-Gonzalez; F Matthew Kuhlmann; Cristina Galan-Rodriguez; Luciana Madeira da Silva; Manuel Saldivia; Caitlin E Karver; Ana Rodriguez; Stephen M Beverley; Miguel Navarro; Michael P Pollastri
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23
View more
  8 in total

1.  Novel Effects of Lapatinib Revealed in the African Trypanosome by Using Hypothesis-Generating Proteomics and Chemical Biology Strategies.

Authors:  Paul J Guyett; Ranjan Behera; Yuko Ogata; Michael Pollastri; Kojo Mensa-Wilmot
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.

Authors:  Jennifer L Woodring; Kelly A Bachovchin; Kimberly G Brady; Mitchell F Gallerstein; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2017-10-06       Impact factor: 6.514

3.  Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.

Authors:  Jennifer L Woodring; Ranjan Behera; Amrita Sharma; Justin Wiedeman; Gautam Patel; Baljinder Singh; Paul Guyett; Emanuele Amata; Jessey Erath; Norma Roncal; Erica Penn; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  ACS Med Chem Lett       Date:  2018-09-04       Impact factor: 4.345

Review 4.  Novel lead compounds in pre-clinical development against African sleeping sickness.

Authors:  Michael Berninger; Ines Schmidt; Alicia Ponte-Sucre; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-07-31       Impact factor: 3.597

5.  Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.

Authors:  William Devine; Jennifer L Woodring; Uma Swaminathan; Emanuele Amata; Gautam Patel; Jessey Erath; Norma E Roncal; Patricia J Lee; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

6.  Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.

Authors:  Kristina Kesely; Panae Noomuna; Michal Vieth; Philip Hipskind; Kasturi Haldar; Antonella Pantaleo; Francesco Turrini; Philip S Low
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

7.  Design, synthesis, crystal structure and anti-plasmodial evaluation of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives.

Authors:  Kavita Pal; Md Kausar Raza; Jenny Legac; Md Ataur Rahman; Shoaib Manzoor; Philip J Rosenthal; Nasimul Hoda
Journal:  RSC Med Chem       Date:  2021-05-18

Review 8.  Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents.

Authors:  Prisca Lagardère; Cyril Fersing; Nicolas Masurier; Vincent Lisowski
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.